20 19 Roche yearbook

Recently, ProClinical, a world-renowned talent recruitment company in the field of life sciences, ranked the top ten pharmaceutical companies in the world 20 19 according to the income of global multinational pharmaceutical companies:

Pfizer 1

Revenue in 20 18: USD 53.7 billion (pharmaceutical business, the same below).

Year-on-year growth: 2.3%

Pfizer is the largest multinational pharmaceutical company in the world. This research-based company has a variety of product portfolios, covering immunology, oncology, neuroscience and rare diseases. Although the income growth rate is not large, 20 18 is still a very successful year for Pfizer.

Many new drugs of Pfizer have been approved by FDA, especially in the field of cancer. In addition, many of its best-selling products have been protected by patents for many years. Pfizer's main products (including Ibrance, Eliquis and Xeljanz) have increased significantly.

2. [Last name] Roach

20 18 revenue: USD 45.6 billion.

Year-on-year growth: 2.7%

Roche, a Swiss pharmaceutical company, was the second largest pharmaceutical company in the world in 20 19, with 94,442 employees worldwide. The company has developed innovative drugs and equipment for many key indications, such as oncology, immunology, infectious diseases and neuroscience. The annual growth rate of the pharmaceutical sector is 2.7%, and the revenue of the top three products accounts for 40% (US$ 57.2 billion) of Roche's total revenue in 20 18.

Roche's best-selling drugs Herceptin, Avastin and Rituximab are also the top anticancer drugs in the world. Severan Schwan, CEO of Roche, reported that in 20 18 years, new drugs accounted for 90% of the company's growth, especially the new drug Ocrevus for treating multiple sclerosis, which was called the most successful new drug in Roche's history.

3. Johnson Company

20 18 revenue: USD 40.7 billion.

Year-on-year growth rate: 12. 1%

Johnson & Johnson Company was founded more than 30 years ago. It has become a well-known big brand because of popular consumer goods such as Aveeno, Neutrogena and Listerine. It is worth noting that the growth of Johnson & Johnson 12. 1% was partly due to the acquisition of Actelion, a biopharmaceutical company in 20 17, and the products in its pulmonary hypertension portfolio brought 3.4% growth to Johnson & Johnson in 20 18. Other growth drivers include the best-selling drugs Stelara, Darzalex and Zytiga.

4.sanofi

20 18 revenue: 39.3 billion dollars.

Year-on-year growth rate: 7. 1%

The pharmaceutical revenue of French pharmaceutical company Sanofi increased by 7. 1% in 20 18 years, accounting for most of the company's total revenue. More than 25% of the income comes from Sanofi's three best-selling drugs, namely Lan Tu, an insulin injection for treating diabetes, Lovenox, an anticoagulant for preventing thrombosis, and Aubagio, a drug for treating multiple sclerosis.

5. Merck

20 18 revenue: USD 37.7 billion.

Year-on-year growth rate: 12.2%

Merck, an American pharmaceutical company, develops new drugs, vaccines and biological agents in the fields of cardiology, oncology, endocrinology and epidemiology. Since 20 17, the company's revenue has increased by 12.2%, which is due to the continuous success of Merck's best-selling drugs: cancer immunotherapy Keytruda, HPV vaccine Gardasil and diabetes drug Januvia.

6. Novartis

20 18 revenue: USD 34.9 billion.

Year-on-year growth: 5.5%

Swiss Novartis' revenue in 20 18 increased by 5.8% compared with the data in 20 17, although its best-selling drugs are facing the market competition of generic drugs, such as the best-selling anti-tumor drug Gleevec and the best-selling antihypertensive drugs hydrochlorothiazide (Diovan) and amlodipine (Exforge).

In order to cope with these losses, Novartis spent 18% of its total revenue in 20 17 years on research and development. At present, Novartis's best-selling drugs are Gilenya for the treatment of multiple sclerosis and Lucentis for patients with ocular degenerative diseases.

7. Albertville

20 18 revenue: 32.8 billion dollars.

Year-on-year growth rate: 16.2%

The research-oriented American biopharmaceutical company AbbVie maintained its position in the list. Compared with the statistical data of medical income in 20 17 years, AbbVie increased by 16.2%.

AbbVie recently announced that its most anticipated drug, upadacitinib, will be used to treat moderate to severe atopic dermatitis, and was designated as a breakthrough drug by FDA. This is just one of many promising drugs in Alberto's product portfolio.

8. Amgen

20 18 revenue: 23.7 billion dollars.

Year-on-year growth: 3.5%

Amgen is an American biopharmaceutical company headquartered in California, USA, focusing on the research and development of cardiovascular diseases, oncology, bone health, neuroscience, nephrology and inflammation. Amgen's ranking is attributed to the success of various products, including Repatha (up 72% year-on-year), BLINCYTO (up 365,438+0% year-on-year) and Prolia (up 65,438+06% year-on-year).

At the beginning of 20 19, Amgen was selected as one of the most respected companies in the pharmaceutical industry by Fortune magazine, and ranked fifth among the most innovative companies in 20 19.

9. GlaxoSmithKline Company

20 18 revenue: 23.3 billion dollars.

Year-on-year growth rate: 2%

GlaxoSmithKline (GSK) is a British pharmaceutical company with powerful innovative drugs. The company focuses on a wide range of therapeutic fields, but it is particularly successful in the fields of HIV/AIDS, respiratory tract and vaccines.

Compared with the data of 20 17, GlaxoSmithKline's revenue growth rate is 2%, and the best-selling HIV drugs Trivicay and Triumeq, Ellipta used for asthma and chronic obstruction, and another asthma drug, mepolizumab (Nucala), all promoted the sales growth.

Last year, Shingrix, a product used by GlaxoSmithKline to treat herpes zoster virus, was approved, with sales reaching 784 million pounds.

10, Bristol-Myers Squibb

20 18 revenue: 22.6 billion dollars.

Year-on-year growth rate: 8.7%

Bristol-Myers Squibb is an American pharmaceutical company headquartered in new york. BMS focuses on four key therapeutic areas: oncology, cardiovascular, immunology and fibrosis. The company's strong growth in 20 18 was partly attributed to the continuous success of the main drugs Oppo (cancer) and Eliquis (blood thinner).

BMS plans to acquire Celgene (an innovative tumor biotechnology) at the beginning of 20 19, which may further promote the success of BMS. (Sun Huan/Compiled)

References:

①ProClinical website: Who are the top pharmaceutical companies in the world 10? (20 19)